Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - Am Heart Assoc
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis from DEFINE-HF …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - scholars.northwestern.edu
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis from DEFINE-HF …
ME Nassif, SL Windsor, K Gosch… - Circulation …, 2023 - utsouthwestern.elsevierpure.com
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
[HTML][HTML] Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From …
ME Nassif, SL Windsor, K Gosch… - Circulation. Heart …, 2023 - ncbi.nlm.nih.gov
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis from DEFINE-HF …
ME Nassif, SL Windsor, K Gosch… - Circulation …, 2023 - mayoclinic.elsevierpure.com
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF …
ME Nassif, SL Windsor, K Gosch, BA Borlaug… - Circulation. Heart …, 2023 - europepmc.org
Background Patients with heart failure (HF) have a high burden of symptoms and physical
limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium …
limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF …
ME Nassif, SL Windsor, K Gosch… - Circulation. Heart …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Patients with heart failure (HF) have a high burden of symptoms and physical
limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium …
limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium …
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis from DEFINE-HF …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - pure.johnshopkins.edu
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …